Kohjin Bio Past Earnings Performance
Past criteria checks 1/6
Kohjin Bio's earnings have been declining at an average annual rate of -53.7%, while the Biotechs industry saw earnings growing at 18.4% annually. Revenues have been growing at an average rate of 0.6% per year. Kohjin Bio's return on equity is 11.5%, and it has net margins of 8.1%.
Key information
-53.7%
Earnings growth rate
-53.7%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | 0.6% |
| Return on equity | 11.5% |
| Net Margin | 8.1% |
| Next Earnings Update | 14 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kohjin Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,770 | 384 | 1,284 | 0 |
| 31 Mar 23 | 4,742 | 829 | 1,186 | 0 |
| 31 Mar 22 | 3,947 | 587 | 1,069 | 0 |
Quality Earnings: 177A has high quality earnings.
Growing Profit Margin: 177A's current net profit margins (8.1%) are lower than last year (17.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 177A's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: 177A's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 177A had negative earnings growth (-53.7%) over the past year, making it difficult to compare to the Biotechs industry average (-53.7%).
Return on Equity
High ROE: 177A's Return on Equity (11.5%) is considered low.